BioSpace News Archive

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference, June 15-16, 2020. Raj Mehra, Ph.D., Chairman and CEO, will host meetings via conference calls. For additional information about the Benchmark Co

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in its Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients. The study, named ESCAPE (Nº EudraCT: 2020-001618-39), is an open-label, randomized, double arm Phas

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today announced that the results from its pivotal cellulite trial have been accepted for virtual video presentation at the American Academy of Dermatology (AAD) 2020 Virtual Meeting, being held June 12-14, 2020 online at aad.org.

Dalrada Health Products, the wholly owned subsidiary of Dalrada Financial Corp. (OTC Pink: DFCO) announced the appointment of Gregg Silvers as the VP of Product Development for the GlanHealth suite of sanitizing products.

Signs Development Agreement with International Consortium; Royalties Will be Based on Commercialization of Future Products Clinical Results in GvHD Studies May be Beneficial in COVID-19 and CAR-T Cytokine Storm manifestations [18-May-2020] TEL AVIV, Israel , May 18, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative tec

Vifor Fresenius Medical Care Renal Pharma and ChemoCentryx, Inc., announced topline data from a forty-six patient phase-II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis.

Tumor cells inhibit myeloid cell phagocytosis and dendritic cell antigen presentation through the novel “Don’t eat me” signal mediated by CLEC-1

StageZero Life Sciences announced that it will release its Fourth Quarter 2019 operational results before markets open on Tuesday, May 19, 2020.

Dyadic International, Inc., a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the quarter ended March 31, 2020, and recent developments.

Decision Diagnostics Corp. through its subsidiary Pharma Tech Solutions, Inc. the manufacturers and design specifiers for the GenViro! Covid-19 :15 test professional Swift Kit, announced that it received detailed media coverage for its individual home testing version of the Swift Kit.